First Time Loading...

Fusion Pharmaceuticals Inc
NASDAQ:FUSN

Watchlist Manager
Fusion Pharmaceuticals Inc Logo
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
Watchlist
Price: 21.45 USD -0.19%
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

FUSN Price Targets Summary
Fusion Pharmaceuticals Inc

Wall Street analysts forecast FUSN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FUSN is 22.1 USD with a low forecast of 20.2 USD and a high forecast of 25.2 USD.

FUSN Lowest Forecast
Wall Street Target
20.2 USD
6% Downside
FUSN Average Forecast
Wall Street Target
22.1 USD
3% Upside
FUSN Highest Forecast
Wall Street Target
25.2 USD
17% Upside
Lowest
Price Target
20.2 USD
6% Downside
Average
Price Target
22.1 USD
3% Upside
Highest
Price Target
25.2 USD
17% Upside

FUSN Last Price Targets
Fusion Pharmaceuticals Inc

The latest public price target was made on Mar 19, 2024 by Matthew Harrison from Morgan Stanley , who expects FUSN stock to drop by 2% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Matthew Harrison
Morgan Stanley
21 USD
Downside 2%
1 month ago
Mar 19, 2024
Morgan Stanley Downgrades Fusion Pharmaceuticals (FUSN) to Equalweight
StreetInsider
Suji Jeong
Jefferies
21 USD
Downside 2%
1 month ago
Mar 19, 2024
Jefferies Downgrades Fusion Pharmaceuticals (FUSN) to Hold
StreetInsider
Jeff Jones
Oppenheimer
13 USD
Downside 39%
7 months ago
Sep 29, 2023
Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer
Benzinga
Matthew Harrison
Morgan Stanley
Price Target 21 USD
Upside/Downside 2%
View Source
Suji Jeong
Jefferies
Price Target 21 USD
Upside/Downside 2%
View Source
Jeff Jones
Oppenheimer
Price Target 13 USD
Upside/Downside 39%
View Source
Fusion Pharmaceuticals Inc Competitors:
Price Targets
ABBV
Abbvie Inc
16% Upside
BBIO
BridgeBio Pharma Inc
82% Upside
ELYM
Eliem Therapeutics Inc
56% Downside
2256
Abbisko Cayman Ltd
152% Upside
ABBV
Abbvie Inc
16% Upside
BBIO
BridgeBio Pharma Inc
82% Upside
ELYM
Eliem Therapeutics Inc
56% Downside
2256
Abbisko Cayman Ltd
152% Upside
BIOG B
Biogaia AB
36% Upside
NIOX
Niox Group PLC
10% Upside
B
BLRX
BioLine RX Ltd
82% Downside
A
298380
ABL Bio Inc
44% Upside

Revenue
Forecast

Revenue Estimate
Fusion Pharmaceuticals Inc

The compound annual growth rate of Fusion Pharmaceuticals Inc's revenue for the next 3 years is 64%.

N/A
Past Growth
64%
Estimated Growth
Estimates Accuracy
27%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Fusion Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Fusion Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-51%
Average Miss
What are analyst estimates?

See Also

Summary
FUSN intrinsic value, competitors valuation, and company profile.
DCF Valuation
FUSN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FUSN stock valuation using valuation multiples.
Wall Street Estimates
FUSN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FUSN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FUSN's stock price target?
Price Target
22.1 USD

According to Wall Street analysts, the average 1-year price target for FUSN is 22.1 USD with a low forecast of 20.2 USD and a high forecast of 25.2 USD.

What is Fusion Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
64%

The compound annual growth rate of Fusion Pharmaceuticals Inc's revenue for the next 3 years is 64%.

ALPHA SPREAD
Join more than 134,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.